CRISPR Therapeutics Safety & QC
Bystander mutation testing, off-target profiling, and unwanted-mutation screening for CRISPR-based therapy developers.
As CRISPR-based therapies move into the clinic, characterising the unintended consequences of gene editing becomes essential. We are developing geneSlice-powered assays to support CRISPR therapeutics developers with bystander mutation testing, off-target profiling, and unwanted-mutation screening.
Three assay capabilities in active development
Bystander mutation testing
For base editors (ABE/CBE) and HDR-based approaches: what other changes occur at the target site?
Off-target profiling
Functional assessment of editing at unintended genomic locations.
Unwanted-mutation screening
Comprehensive profiling of unintended edits introduced during therapeutic editing.
Get in touch
This service is currently in active development. If you're developing a CRISPR-based therapy and want to discuss early access or scoping for your programme, we'd like to hear from you.